Baloxavir

Small molecule

IInsight Therapeutics, LLC

Baloxavir is one of 19 small molecule programs targeting Influenza. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

InfluenzaActive, not recruiting

InfluenzaPhase 2/Phase 3

Active, not recruiting

Competition

Competitive Landscape

1053 competitors in Influenza

#DrugCompanyPhaseTrials

Fluzone

Sanofi

Preclinical

16 2

Fluzone

GSK

Preclinical

37 3

Avigan

AAppili Therapeutics Inc.

Preclinical

6 4

COMIRNATY

Pfizer

Preclinical

1 5

Antihistamine

Arrowhead Pharmaceuticals

Preclinical

1 6

Focetria

CChiltern Pesquisa Clinica Ltda

Preclinical

1 7

Influenza A/H5N1

NNational Institute of Allergy and Infectious Diseases (NIAID)

Preclinical

14 8

Fluvirin

Novartis

Preclinical

3 9

Diphtheria-Tetanus-Acellular Pertussis Vaccine

CanSino Biologics Inc.

Preclinical

1 10

Afluria

NNational Heart, Lung, and Blood Institute (NHLBI)

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 2Recruiting

Influenza

NCT05648448

Q2 2027

Phase 3Not yet recruiting

Respiratory Infections

NCT07314905

Clinical

Trials by Indication[1]

Influenza3 trials

A Phase 2 Trial Comparing Antiviral Treatments in Early Symptomatic Influenza

Recruiting·UUniversity of Oxford·Phase 2·NCT05648448·3,000 enrolled

COmbination Therapy With Baloxavir and Oseltamivir 1 for Hospitalized Patients With Influenza (The COMBO Trial 1)

Unknown status·BBassett Healthcare·Phase 2/3·NCT04327791·60 enrolled

Baloxavir Versus Oseltamivir for Nursing Home Influenza Outbreaks

Unknown status·IInsight Therapeutics, LLC·Phase 4·NCT05012189·1,000 enrolled

Respiratory Infections1 trial

Adaptive Platform Trial of Treatments for Respiratory Infections in Community Settings (TreatResp)

Not yet recruiting·UUnity Health Toronto·Phase 3·NCT07314905·264 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Baloxavir. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Baloxavir compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Baloxavir. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Insight Therapeutics, LLC company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: IInsight Therapeutics, LLC

Baloxavir

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q2 2027

Trials by Indication[1]

Influenza3 trials

Respiratory Infections1 trial

References

Drug Info

Quick Facts

Related News